Recent Finacing
Recent Raise
Judo Bio develops oligonucleotide therapeutics using STRIKE platform to deliver ligand‑siRNA conjugates via megalin-mediated receptor uptake for targeted gene silencing in kidney cells, advancing lead programs to clinical studies.
